In this photograph illustration, the Sage Therapeutics emblem of a biopharmaceutical firm seen on a smartphone and on a laptop display.
Pavlo Gonchar | SOPA Images | Lightrocket | Getty Images
Shares of Sage Therapeutics fell more than 50% on Monday after the Food and Drug Administration approved the biotech firm’s oral drug zuranolone for postpartum depression, however not for major depressive disorder, a much bigger potential market.
Shares of Biogen, which collectively developed the therapy with Sage, had been roughly flat.
associated investing information
The FDA’s approval late Friday made Zuranolone the primary oral therapy for postpartum depression, a typical complication that impacts one in eight ladies throughout and after being pregnant and hinders their means to operate usually.
The two firms additionally applied for approval of Zuranolone for main depressive dysfunction, often known as scientific depression. But the FDA stated they didn’t present sufficient proof of the drug’s effectiveness in treating the situation, which impacts a a lot bigger inhabitants of sufferers.
Clinical depression impacts roughly 17.3 million American adults, or about 7% of the folks ages 18 and older, in a given yr.
Zuranolone had the potential for $1 billion in peak gross sales, in contrast with $250 million to $500 million for postpartum depression, Jefferies analyst Michael Yee stated in a analysis be aware Sunday.
He stated scientific depression “was actually the large upside driver right here” for the businesses, whereas postpartum depression is “a lot smaller and is probably not massively worthwhile.”
Wells Fargo analyst Mohit Bansal additionally stated the scientific depression market contributed to 85% of the agency’s future gross sales estimates for Zuranolone. But “there could possibly be a silver lining because the pricing energy could also be increased” in postpartum depression, he wrote in a Sunday analysis be aware.
Sage and Biogen haven’t disclosed Zuranolone’s value for postpartum depression therapy.
The FDA stated further research is likely to be required to help the drug’s approval for scientific depression.
But Yee famous that Biogen is unlikely to “rapidly transfer ahead on one other late-stage research” on the drug for scientific depression because the firm is focusing on saving costs and lately introduced layoffs.